Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 14.37 -2.84% -0.42
PTLA closed down 2.84 percent on Friday, January 17, 2020, on 1.2 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical PTLA trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -2.84%
Lower Bollinger Band Walk Weakness -2.84%
Wide Bands Range Expansion -2.84%
Oversold Stochastic Weakness -2.84%
Slingshot Bearish Bearish Swing Setup -3.56%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Clinical Medicine Surgery Inflammation Seattle Genetics Spinal Muscular Atrophy Inflammatory Disorders Thrombosis Astellas Pharma Anticoagulants Factor X Hematologic Disorders Portola Pharmaceuticals

Is PTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Jan 19 PTLA LOSSES ALERT: Bernstein Liebhard Encourages Investors With Losses in Portola Pharmaceuticals Inc. to Contact the Firm and Reminds Them of an Important Filing Deadline
Jan 18 IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Portola Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Jan 18 Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. (PTLA)
Jan 18 PTLA LOSSES ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Portola Pharmaceuticals, Inc., and Encourages Investors With Losses to Contact the Firm
Jan 17 The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Portola Pharmaceuticals, Inc. (PTLA)
Jan 17 INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Portola Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Jan 17 SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Portola Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Jan 17 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Portola Pharmaceuticals Inc. - PTLA
Jan 17 PORTOLA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Jan 17 INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Portola Pharmaceuticals, Inc. Investors
See more PTLA news...

Indicators

Indicator Value
52 Week High 37.95
52 Week Low 13.42
Average Volume 1,472,990
200-Day Moving Average 28.29
50-Day Moving Average 25.37
20-Day Moving Average 21.71
10-Day Moving Average 18.37
Average True Range 1.46
ADX 49.23
+DI 9.19
-DI 48.62
Chandelier Exit (Long, 3 ATRs ) 22.41
Chandelier Exit (Short, 3 ATRs ) 17.80
Upper Bollinger Band 31.31
Lower Bollinger Band 12.10
Percent B (%b) 0.12
BandWidth 88.50
MACD Line -3.25
MACD Signal Line -2.34
MACD Histogram -0.907
Fundamentals Value
Market Cap 827.64 Million
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -3.16
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.27
Resistance 3 (R3) 15.33 15.09 15.12
Resistance 2 (R2) 15.09 14.86 15.06 15.07
Resistance 1 (R1) 14.73 14.72 14.61 14.67 15.02
Pivot Point 14.49 14.49 14.43 14.46 14.49
Support 1 (S1) 14.13 14.26 14.01 14.07 13.72
Support 2 (S2) 13.89 14.12 13.86 13.67
Support 3 (S3) 13.53 13.89 13.62
Support 4 (S4) 13.47